email article
A personalized algorithm was developed by researchers in England to recommend retreatment with rituximab (Rituxan) among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with the intention of preventing relapses while lowering the risks of infection.
In a multivariable analysis of 60 rituximab-treated patients with ANCA-associated vasculitis followed over a decade, predictors of a longer time to relapse were concomitant immunosuppression (HR 0.48, 95% CI 0.24-0.94,
P=0.034), complete response at 6 months (HR 0.24, 95% CI 0.12-0.50,
P